Market analysts' consensus outlook for the coming year seems optimistic, with earnings becoming less negative, reaching -US$104.27M in 2019. In the following year, earnings are predicted to hover around the same level before rising to -US$51.41M in 2021.
While it’s useful to be aware of the growth each year relative to today’s figure, it may be more insightful analyzing the rate at which the business is growing every year, on average. The advantage of this technique is that it removes the impact of near term flucuations and accounts for the overarching direction of MannKind's earnings trajectory over time, which may be more relevant for long term investors. To calculate this rate, I put a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is 53.35%. This means, we can assume MannKind will grow its earnings by 53.35% every year for the next couple of years.
Next Steps:
For MannKind, I've put together three relevant factors you should further research:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Valuation: What is MNKD worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether MNKD is currently mispriced by the market.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of MNKD? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About NasdaqGM:MNKD
MannKind
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
Reasonable growth potential with proven track record.
Similar Companies
Market Insights
Community Narratives
